TruSight Oncology Platform Reagents
A set of NGS platform reagents for detecting cancer variants, using an enrichment-based method to simultaneously analyze DNA and RNA. Gene content is not included.
Read More...
Product Highlights
These enrichment-based next-generation sequencing (NGS) reagents enable simultaneous analysis of DNA and RNA, and can cover a wide range of cancer variant types. This methodology provides laboratories with a deep view into the genetics of cancer.
- Accurate Results from Low-Quality Samples1
Enables variant detection with as little as 40 ng DNA and RNA input, maximizing the results from precious formalin-fixed, paraffin-embedded (FFPE) samples. - Supports Comprehensive Coverage of Cancer-Related Variants
Allows the assessment of multiple variant types in one assay using DNA and RNA which creates efficiencies in sample usage, time, and cost.
- Integrated, Streamlined Workflow
DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis. - Flexible Applications
Enrichment-based workflow allows for a wide variety of content, input types, and applications.
Frequently Purchased Together
Specifications
Product Literature
Analysis of TruSight Oncology 500 data with PierianDx Clinical Genomics Workspace Software
Brochure | PDF < 1 MB
TruSight Oncology 500 Demo Program Flyer
Brochure | PDF < 1 MB
Analysis of TMB and MSI Status with TruSight Oncology 500
Application note | HTML
Optimizing RNA input to detect gene fusions with TruSight Oncology 500 High-Throughput
Technical note | PDF < 1 MB
A dedicated support section is not currently available for this product
TruSight Oncology 500
Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI, and HRD) from FFPE tissue.
TruSight Oncology 500 ctDNA v2
Enable CGP with a pan-cancer panel capable of detecting key IO gene signatures (TMB, MSI) plus all main variant classes from ctDNA in blood plasma.
TruSight Tumor 170
Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.
References
- Data on file. Illumina, Inc. March 2017.